Randomized Phase II Trial of Sacituzumab Govitecan-hziy (SG) and Bevacizumab versus Standard of Care Carboplatin, Pegylated Liposomal Doxorubicin (PLD) and Bevacizumab in Patients with Platinum-Sensitive Ovarian Cancer that has Progressed on Prior Maintenance PARP Inhibitor Therapy